Business
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting
BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster presentations at
About this update from Tango Therapeutics, Inc.
[{"type":"text","content":"BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida. Abstract titles, presentation information and text, if provided by the meeting organizers, are currently available on the AACR 2023 Annual Meeting website. Abstracts accepted for oral presentation Title: TNG908, a brain-penetrant MTA-cooperative PRMT5 inhibitor, is efficacious in preclinical glioblastoma modelsAbstract #: 3452Session title: Novel Antitumor Agents and TargetsPresenter: Kimberly Briggs, Ph.D., Associate Director, Tango TherapeuticsSession Date and Time: April 17, 2023, 2:30-4:30 p.m. ET TNG908 is brain penetrant in non-human primates, suggesting the potential for clinical efficacy in MTAP-deleted glioblastoma (GBM). Oral administration of TNG908 is efficacious in MTAP-deleted xenograft models across histologies, including GBM. TNG908 treatment increased median survival by three-fold in a murine GBM orthotopic model compared to controls. TNG908 is being studied in an ongoing Phase 1/2 trial for patients with MTAP-deleted tumors, including those with GBM. Title: TNG260: A novel, orally active, CoREST-selective deacetylase inhibitor for the treatment of STK11-mutant cancers Session Title: New Drugs on the Horizon Session: Part 3 Presenter: Leanne Ahronian, Ph.D., Senior Scientist, Tango Therapeutics Session Date and Time: April 17, 2023, 10:15-11:45 a.m. ET Abstracts accepted for poster presentation Title: Characterization of the clinical development candidate TNG348 as a potent and selective inhibitor of USP1 for the treatment of BRCA1/2mut cancersAbstract #: 4968Format: Poster PresentationSession Title: Novel Targets and Pathways Session Date and Time: April 18, 2023, 1:30-5:00 p.m. ET Title: TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumorsAbstract #: 4970Format: Poster PresentationSession Title: Novel Targets and PathwaysSession Date and Time: April 18, 2023, 1:30-5:00 p.m. ET About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the...